# **Indiana University Melvin and Bren Simon Comprehensive Cancer Center**

## **ANNOUNCEMENT**

# "Near-Miss" NIH R01 Initiative

IUSCCC Support for High Quality Grant Applications Missing NIH Pay line

**Purpose:** To provide funding to support cancer focused PI-directed applications to the National Institutes of Health with high potential for obtaining external funding that **have been reviewed once and missed the NIH pay line**. The goal is to increase cancer focused NIH funding base in the IUSCCC. Non-NCI applications should have significant cancer relevance.

## Eligibility:

- Full & Associate Level IUSCCC Members ONLY:
  - Submitted an NIH R01, U01, R42, R44, P01 or SPORE.
  - R01 application that scored equal to or below a 30% and are re-submitting the proposal to NCI /NIH (i.e. A1s only)
  - For an R42 or R44 Phase II Grant (STTR/SBIR) submitted to the NCI/NIH, a score equal to or below 40.
  - For P01, SPORE, other R01 institutes applications will be evaluated on a case-by-case basis. The abstract and specific aim page must describe cancer relevance of the project
- Submit request for IUSCCC funding only one time per grant.

#### Interested?

Investigators wishing to apply to this funding mechanism must first submit a draft cover letter (described below) to one of the IUSCCC Translational Research Coordinators (Crystal Baker and Kaitlin Condron) for approval by the IUSCCC Executive Committee before working with the Coordinator to submit a full application.

Once approved, the link for submitting the online application will be sent.

## For non-NCI applications, cancer relevance will also be evaluated.

Please note that you will be submitting through the Indiana CTSI's grants management software WebCAMP. The WebCAMP user's guide is available under the funding announcement here

#### Applications for funding must use the application form found here and include:

- A cover letter describing the rationale for the request and anticipated date of external grant resubmission.
- For non-NCI applications, cancer relevance should be addressed in the cover letter.
- A 1-page proposal for use of the pilot funding to include clear plans for how the pilot funding will be used to address reviewer critiques
- A <u>timeline and/or map</u> (via ITRAC mechanism) for accomplishing the proposed work and identified benchmarks necessary for high likelihood for achieving a fundable score upon new submission (to be completed with Crystal (crybanks@iupui.edu) or Kaitlin (<u>kcondron@iu.edu</u>). Please allow two weeks for completing this requirement.
- A proposed budget and justification for the funding. Maximum allowable amount for R01, R42 and R44 grants is \$50K with P01 and SPORE funding amounts evaluated on a case-by-case basis. Funding for meritorious projects will be able to begin ~ eight weeks after submission.
- Specific Aims page of the originally submitted grant application
- The reviewer critiques of the application with score and percentile.
   The proposed responses to those critiques and plans on how the application will be improved for resubmission.

#### **Review Process**

- Review of application and funding will be performed by a committee comprised of the IUSCCC Program
  Leaders and a final review for determination of funding will be performed by the IUSCCC Executive
  Committee.
- Applications must be to the NIH. No exceptions.
- Submission can be at any time.
- The review committee will consider the overall probability of future funding for the project as reflected in the
  priority score, reviewer critiques, response of the PI to those critiques, and how the application will be
  modified for resubmission.
- Additionally, evaluation will include demonstrated ongoing efforts of the PI in obtaining funding for the
  project (e.g. list of grant applications submitted within the past year), and the level of involvement of the PI
  in the IUSCCC. Each application will be considered on its' own merit.

## Post-award management

All award recipients must agree to comply with IUSCCC internal award funding reporting requirements as described below.

- 1. Annual progress reporting during the life of the award as needed by the IUSCCC for reporting metrics to the NCI.
- 2. Annual follow up for 5 years after the expiration date of the funding period, to provide (a) publications (b) grants submitted; (c) grants funded that used data generated by core, and (d) intellectual property. This information will assist the IUSCCC in their grant renewal.
- 3. By accepting this award recipients agree to notify the IUSCCC in writing if leaving the university prior to the closure of this project. The IUSCCC must approve all transfers to a new PI.
- 4. When publishing your data, you must acknowledge receipt of IUSCCC support in any presentation or publication of work by indicating that preliminary data was funded by the IU Simon Comprehensive Cancer Center

#### Contact information:

Crystal Baker (<a href="mailto:crybanks@iupui.edu">crystal Baker (<a href="mailto:crybanks@iupui.edu">crybanks@iupui.edu</a>) and Kaitlin Condron (<a href="mailto:kcondron@iu.edu">kcondron@iu.edu</a>) for submission support (<a href="mailto:mapping/timeline">mapping/timeline</a>) or Mark R. Kelley (<a href="mailto:mkelley@iu.edu">mkelley@iu.edu</a>) for RFA inquires.